Back

Hexem Bio raises $15.5 million to develop blood-stem-cell rejuvenation therapy

Verifying
  • Hexem Bio raised funding to develop its Synthetic Human Yolk Sac stem-cell platform.
  • The round totaled $15.5 million, including $2 million from Korea Investment Partners.
  • Hexem Bio plans first-in-human dosing in 2027 after preclinical and manufacturing preparations.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.